Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

被引:18
|
作者
Rommasi, Foad [1 ]
Nasiri, Mohammad Javad [2 ]
Mirsaeidi, Mehdi [3 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[3] Univ Miami, Miller Sch Med, Dept Pulm & Crit Care, Miami, FL 33136 USA
关键词
SARS-CoV-2; Pathophysiology; COVID-19; treatment; Inflammatory responses; Immunosuppressive agents; Cytokine storm; NECROSIS-FACTOR-ALPHA; CORONAVIRUS DISEASE 2019; RHEUMATOID-ARTHRITIS; CLINICAL PHARMACOKINETICS; RECEPTOR ANTAGONIST; IN-VITRO; ABSOLUTE BIOAVAILABILITY; COLCHICINE THERAPY; CYTOKINE STORM; MELATONIN;
D O I
10.1007/s11010-021-04325-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
引用
收藏
页码:711 / 726
页数:16
相关论文
共 50 条
  • [1] Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
    Foad Rommasi
    Mohammad Javad Nasiri
    Mehdi Mirsaeidi
    Molecular and Cellular Biochemistry, 2022, 477 : 711 - 726
  • [2] Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection
    Bahari, Zahra
    Jangravi, Zohreh
    Ghoshooni, Hassan
    Afarinesh, Mohammad Reza
    Meftahi, Gholam Hossein
    INFLAMMATION RESEARCH, 2021, 70 (04) : 389 - 405
  • [3] Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection
    Zahra Bahari
    Zohreh Jangravi
    Hassan Ghoshooni
    Mohammad Reza Afarinesh
    Gholam Hossein Meftahi
    Inflammation Research, 2021, 70 : 389 - 405
  • [4] Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review
    Khodashahi, Rozita
    Naderi, Hamidreza
    Bojdy, Amin
    Khodashahi, Mandana
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2020, 16 (03) : 165 - 183
  • [5] COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology
    Degirmenci, Mehmet Fatih Kagan
    Yalcindag, F. Nilufer
    Tugal-Tutkun, Ilknur
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2021, 51 (04): : 231 - 242
  • [6] Oncologic immunomodulatory agents in patients with cancer and COVID-19
    Justin Jee
    Aaron J. Stonestrom
    Sean Devlin
    Teresa Nguyentran
    Beatriz Wills
    Varun Narendra
    Michael B. Foote
    Melissa Lumish
    Santosha A. Vardhana
    Stephen M. Pastores
    Neha Korde
    Dhwani Patel
    Steven Horwitz
    Michael Scordo
    Anthony F. Daniyan
    Scientific Reports, 11
  • [7] Oncologic immunomodulatory agents in patients with cancer and COVID-19
    Jee, Justin
    Stonestrom, Aaron J.
    Devlin, Sean
    Nguyentran, Teresa
    Wills, Beatriz
    Narendra, Varun
    Foote, Michael B.
    Lumish, Melissa
    Vardhana, Santosha A.
    Pastores, Stephen M.
    Korde, Neha
    Patel, Dhwani
    Horwitz, Steven
    Scordo, Michael
    Daniyan, Anthony F.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [8] Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action
    Emanuele Rizzo
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393 : 1153 - 1156
  • [9] Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action
    Rizzo, Emanuele
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (07) : 1153 - 1156
  • [10] COVID-19: immunopathology, pathophysiological mechanisms, and treatment options
    van Eijk, Larissa E.
    Binkhorst, Mathijs
    Bourgonje, Arno R.
    Offringa, Annette K.
    Mulder, Douwe J.
    Bos, Eelke M.
    Kolundzic, Nikola
    Abdulle, Amaal E.
    van der Voort, Peter H. J.
    Olde Rikkert, Marcel G. M.
    van der Hoeven, Johannes G.
    den Dunnen, Wilfred F. A.
    Hillebrands, Jan-Luuk
    van Goor, Harry
    JOURNAL OF PATHOLOGY, 2021, 254 (04): : 307 - 331